Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma

International Journal of Cancer

Volumn 107, Issue 1, 2003, Pages 65-73

  Chung, Yih Lin ^a,b   Sheu, Meei Ling ^c   Yen, Sang Hue ^c  

^a KOO FOUNDATION SUN YAT SEN CANCER CENTER   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Bax; Hepatitis C virus; Hepatocellular carcinoma; NS5A; Phenylbutyrate

Indexed keywords

4 PHENYLBUTYRIC ACID; ARYLBUTYRIC ACID DERIVATIVE; DNA FRAGMENT; GLUTATHIONE TRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HYBRID PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; SODIUM HYDROXIDE; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN NS5A;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL FRACTIONATION; CELL NUCLEUS; CONTROLLED STUDY; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SEQUENCE HOMOLOGY; VIRUS CORE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; DNA, VIRAL; FLUORESCENT ANTIBODY TECHNIQUE; HEPATITIS C; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; NUCLEAR LOCALIZATION SIGNALS; PHENYLBUTYRATES; PRECIPITIN TESTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA REPLICASE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 0041914260     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11303     Document Type: Article

References (45)

1. Bergsland EK, Venook AP. Hepatocellular carcinoma. Curr Opin Oncol 2000;12:357-61.
2. Nakakura EK, Choti MA. Management of hepatocellular carcinoma. Oncology 2000;14:1085-98.
3. Sangro B, Rios R, Bilbao I, Beloqui O, Herrero JI, Quiroga J, Prieto J. Efficacy and toxicity of intra-arterial cisplatin and etoposide for advanced hepatocellular carcinoma. Oncology 2002;62:293-8.
4. Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T, Hashimoto-Tamaoki T. Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. Int J Cancer 1998; 76:897-902.
5. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001;313:451-64.
6. Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996;70:4438-43.
7. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-7.
8. Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997;229:68-76.
9. Honda M, Kaneko S, Shimazaki T, Matsushita E, Kobayashi K, Ping LH, Zhang HC, Lemon SM. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells. Hepatology 2000;31:1351-9.
10. Ghosh AK, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol 1999;80:1179-83.
11. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001;75:1401-7.
12. Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ, Katze MG. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 1999;96:5533-8.
13. Ghosh AK, Majumder M, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein protects against TNF-α mediated apoptotic cell death. Virus Res 2000;67:173-8.
14. Majumder M, Ghosh AK, Steele R, Zhou XY, Phillips NJ, Ray R, Ray RB. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology 2002;294:94-105.
15. Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, Wang YJ, Kato N, Omata M, Chang FY, Lee SD. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002;21:4801-11.
16. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, Marumo F, Sato C. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995;96:224-30.
17. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C, Ward J. Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 1984;310:1630-4.
18. Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998;90: 1621-5.
19. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994;84:339-43.
20. Olivieri NF, Rees DC, Ginder GD, Thein SL, Brittenham GM, Waye JS, Weatherall DJ. Treatment of thalassemia major with phenylbutyrate and hydroxyurea. Lancet 1997;350:491-2.
21. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998;157:484-90.
22. Kemp S, Wei HM, Lu JF, Braiterman LT, McGuinness MC, Moser AB, Watkins PA, Smith KD. Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 1998;4:1261-8.
23. Gore SD, Weng LJ, Zhai S, Figg WD, Donehower RC, Dover GJ, Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins AL, et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res 2001;7:2330-9.
24. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001;7:2292-300.
25. Madani A. The 8 Kd product of the putative oncogene MTCP-1 is a mitochondrial protein. Oncogene 1995;10:2259-62.
26. Carstea ED, Miller SP, Christakis H, O'Neill RR. Analogues of butyric acid that increase the expression of transfected DNAs. Biophys Biochem Res Comm 1993;192:649-56.
27. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: induction of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6.
28. Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998;17:999-1007.
29. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet 1998;20:259-65.
30. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 1997;94:3668-72.
31. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-3.
32. Korsmeyer SJ. Regulators of cell death. Trends Genet 1995;11:101-5
33. Tschopp J, Thome M, Hofmann K, Meinl E. The fight of viruses against apoptosis. Curr Opin Genet & Dev 1998;8:82-7.
34. Cohen J. The scientific challenge of hepatitis C. Science 1999;285: 26-30.
35. Song J, Fujii M, Wang F, Itoh M, Hotta H. The NS5A protein of hepatitis C virus partially inhibits the antiviral activity of interferon. J Gen Virol 1999;80:879-86.
36. Pawlotsky JM, Germanidis G. The non-structural 5A protein of hepatitis C virus. J Viral Hepat 1999:6:343-56.
37. Gale M Jr, Kwieciszewski B, Dossett M, Nakao H, Katze MG. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999;73:6506-16.
38. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettssheim D, Chang BS, Thompson CB, Wong S, Ng S, Fesik SW. X-ray and NMR structure of human Bcl-xL. an inhibitor of programmed cell death. Nature 1996;381:335-41.
39. Hess JL, Korsmeyer SJ. Life, death and nuclear spots. Nat Genet 1998;20:220-2.
40. Ide Y, Zhang L, Chen M, Inchauspe G, Bahl C, Sasaguri Y, Padmanabhan R. Characterization of the nuclear localization signal and subcellular distribution of hepatitis C virus nonstructural protein NS5A. Gene 1996;182:203-11.
41. Satoh S, Hirota M, Noguchi T, Hijikata M, Handa H, Shimotohno K. Cleavage of hepatitis C virus nonstructural protein 5A by a caspase-like protease(s) in mammalian cells. Virology 2000;270:476-87.
42. Kitanaka C, Namiki T, Noguchi K, Mochizuki T, Kagaya S, Chi S, Hayashi A, Asai A, Tsujimoto Y, Kuchino Y. Caspase-dependent apoptosis of COS-7 cells induced by Bax overexpression: differential effects of Bcl-2 and Bcl-xL on Bax-induced caspase activation and apoptosis. Oncogene 1997;15:1763-72.
43. Han J, Sabbatini P, Perez D, Rao L, Modha D, White E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes & Dev 1996;10: 461-77.
44. Rao L, Modha D, White E. The E1B 19K protein associates with lamins in vivo and its proper localization is required for inhibition of apoptosis. Oncogene 1997;15:1587-97.
45. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.